This site is intended for Healthcare professionals only.

DSM Sinochem Pharmaceuticals Wins Indian Patent Infringement Case


DSM Sinochem Pharmaceuticals Wins Indian Patent Infringement Case

SINGAPORE: DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that the High Court of Delhi has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement in India.

According to DSM Sinochem Pharmaceuticals’ (DSP) wholly owned subsidiaries, DSM Sinochem Pharmaceuticals Netherlands B.V. and DSM Pharmaceuticals India Pvt. Ltd., the High Court of Delhi, India, has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical Co., LTD  (“Weiqida”) for patent infringement of Indian Patent Number 247,301. This patent, which is owned by DSP, relates to amoxicillin trihydrate having a low free water content and processes for the manufacture thereof.

The permanent injunction prevents the manufacture, use, importation, offering for sale and sale of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India, as well as any drug product that utilizes the active pharmaceutical ingredient.
“DSP welcomes the Court’s decision,” said Karl Rotthier, CEO at DSP. “The lawsuit is intended to protect DSP’s world class intellectual property portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology.  DSP will continue to rigorously enforce its IP assets worldwide as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins.”



Source: PRESS RELEASE
0 comment(s) on DSM Sinochem Pharmaceuticals Wins Indian Patent Infringement Case

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted